Insulet Corporation (PODD) Stock Analysis
Recovery setup · Temp Headwind edge
Healthcare · Medical Devices
Wait — supporting gate not met yet. Price is at or below entry $167.43 but weak momentum; below 200-day MA (death cross); critical SEC filing still blocks BUY_NOW. Key risks: Concentration risk — Customer: Distributor A, Distributor B, Distributor C; Concentration risk — Product: Omnipod product platform.
Insulet develops, manufactures, and sells the Omnipod tubeless insulin delivery system for people with insulin-dependent diabetes in 25 countries, alongside drug delivery pods for Amgen's Neulasta. Revenue is primarily from Omnipod pods and PDMs sold through wholesalers and... Read more
Wait — supporting gate not met yet. Price is at or below entry $167.43 but weak momentum; below 200-day MA (death cross); critical SEC filing still blocks BUY_NOW. Key risks: Concentration risk — Customer: Distributor A, Distributor B, Distributor C; Concentration risk — Product: Omnipod product platform. Chart setup: Death cross but MACD improving, RSI 45. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.32, quality 7.6/10, growth 10.0/10). Score 6.6/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, earnings proximity 54d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and SEC filing concern. Suitability: moderate.
Recent developments
updated 2026-06-14Recent Developments — Insulet Corporation
Latest news
- NEWS Insulet (NASDAQ:PODD) Shares Down 8.9% - Here's What Happened - MarketBeat — MarketBeat negative
- NEWS Insulet (PODD) Issues Safety Advisory on Affected Pod Lots - GuruFocus — GuruFocus negative
- NEWS Insulet (PODD) Ends April With Strong Analyst Sentiment Amid Strong Earnings Expectations - Yahoo Finance — Yahoo Finance positive
- NEWS Insulet Stock Sinks After Costly Pod Safety Scare - TipRanks — TipRanks negative
- NEWS William Blair Initiates on Insulet (PODD) With Outperform and Says the Valuation Gap Is Hard to Justify - Insider Monkey — Insider Monkey positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerDistributor A, Distributor B, Distributor C10-K Item 1: 'Distributor A| 27%| | 28%| | 28% Distributor B| 26%| | 26%| | 24% Distributor C| 25%| | 21%| | 19%'
- HIGHProductOmnipod product platform10-K Item 1A: 'We expect to continue to derive nearly all our revenue from our Omnipod product platform'
- MEDIUMcounterpartyAmgen Neulasta Onpro10-K Item 1A: 'Substantially all of our commercialized Drug Delivery revenue consists of sales of a customized version of our product for use in Amgen’s Neulasta Onpro kit under an agreement that expires in December 2028'
Material Events(8-K, last 90d)
- 2026-02-24Item 4.01HIGHInsulet dismissed Grant Thornton LLP (GT) as independent auditor after completion of fiscal year ended December 31, 2025 audit. PricewaterhouseCoopers LLP (PwC) selected as auditor for fiscal year ending December 31, 2026. No disagreement cited.SEC filing →
- 2026-03-04Item 5.02LOWInsulet entered into severance agreement and release dated February 27, 2026 with Ana M. Chadwick, former CFO. No material terms differ from previously disclosed Executive Severance Plan. Original departure disclosed September 2025.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait — supporting gate not met yet. Price is at or below entry $167.43 but weak momentum; below 200-day MA (death cross); critical SEC filing still blocks BUY_NOW. Key risks: Concentration risk — Customer: Distributor A, Distributor B, Distributor C; Concentration risk — Product: Omnipod product platform. Chart setup: Death cross but MACD improving, RSI 45. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.32, quality 7.6/10, growth 10.0/10). Target $218.19 (+45.8%), stop $153.51 (−-2.5%), Setup A.R:R 9.7:1. Score 6.6/10, moderate confidence.
Take-profit target: $218.19 (+51.4% upside). Target $218.19 (+45.8%), stop $153.51 (−-2.5%), Setup A.R:R 9.7:1. Stop-loss: $153.51.
Concentration risk — Customer: Distributor A, Distributor B, Distributor C; Concentration risk — Product: Omnipod product platform; Negative momentum.
Insulet Corporation trades at a P/E of 35.0 (forward 18.5). TrendMatrix value score: 6.0/10. Verdict: Buy (Wait for Entry).
34 analysts cover PODD with a consensus score of 4.2/5. Average price target: $242.
What does Insulet Corporation do?Insulet develops, manufactures, and sells the Omnipod tubeless insulin delivery system for people with...
Insulet develops, manufactures, and sells the Omnipod tubeless insulin delivery system for people with insulin-dependent diabetes in 25 countries, alongside drug delivery pods for Amgen's Neulasta. Revenue is primarily from Omnipod pods and PDMs sold through wholesalers and distributors globally; three distributors each accounted for 25-27% of 2025 total revenues.